SciVac Therapeutics agrees to acquire VBI Vaccines

Rehovot, Israel-based SciVac Therapeutics announced Monday its intention to acquire VBI Vaccines ($VBIV) to form a commercial-stage company with a licensed hepatitis B vaccine and a pipeline of preventative and therapeutic vaccine candidates. VBI will become a wholly owned subsidiary of SciVac, which will rename itself VBI Vaccines. More

Suggested Articles

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.